Health Condition 1: null- Acute pyelonephritis due to ESBL producing enterobacteriaceae
Conditions
Interventions
Intervention1: Ertapenam: This study is an observational data collection process for the patients with acute pyelonephritis who have been treated earlier with ertapenam as per the routine standard cli
Sponsors
MSD Pharmaceuticals
Eligibility
Inclusion criteria
Inclusion criteria: ï??Age: â?§18 years ï??Diagnosis of Acute Pyelonephritis [i.e., patients with fever, flank pain or costvertebral angle tenderness, pyuria (>= 10 white blood cell per high power field)] and confirmed ESBL Enterobacteriaceae (as per CLSI, Vitek-2) on urine culture ï??Patient received Ertapenem therapy (>=3 dose)
Exclusion criteria
Exclusion criteria: ï??Need for concomitant antimicrobials in addition to study therapy ï??A history of coronary heart disease or stroke, serum Creatinine >1.5 mg/dl, albuminuria >40 μg/min, and use of lipid-lowering drugs, aspirin, or other antihypertensive agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures include clinical response of Ertapenem in Acute Pyelonephritis due to ESBL-p Enterobacteriaceae.Timepoint: 10-14 days | — |
Secondary
| Measure | Time frame |
|---|---|
| ï?? Sub group analysis: Ertapenem as empiric &definitive; Response in ESBL-pE.coli ï?? Duration of Ertapenem treatment ï?? Clinical response of Ertapenem as OPAT therapy ï?? Mean bed days saved/patient under OPAT therapy ï?? Total no of days/duration of Ertapenem as OPAT therapy ï?? Cost comparison of Ertapenem under OPAT vs., inpatient settings. Timepoint: â?¢10-14 days â?¢10-14 days â?¢10-14 days â?¢on completion of the study â?¢on completion of the study â?¢on completion of the study | — |
Countries
India
Contacts
Public ContactDrVRamasubramanian
Apollo Hospitals Enterprises limited
Outcome results
None listed